• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Personalis Inc. (Amendment)

    2/10/23 1:52:11 PM ET
    $PSNL
    Medical Specialities
    Health Care
    Get the next $PSNL alert in real time by email
    SC 13G/A 1 tm235555d27_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.  3)*

     

    Personalis, Inc.

     

    (Name of Issuer)

     

    Common stock

     

    (Title of Class of Securities)

     

    71535D106

     

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    xRule 13d-1(b)
    ¨Rule 13d-1(c)
    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 71535D106 13G Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSONS  
    ARK Investment Management LLC  
     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
    (a)¨  
    (b)¨  
    3. SEC USE ONLY  
       
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
    Delaware, United States  
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER  
    5,500,400  
     
    6. SHARED VOTING POWER  
    0  
     
    7. SOLE DISPOSITIVE POWER  
    5,500,400  
     
    8. SHARED DISPOSITIVE POWER  
    0  
     

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    5,500,400  
     
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
    ¨  
     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
    11.96%  
     
    12. TYPE OF REPORTING PERSON  
    IA  
     

     

     

     

     

    CUSIP No. 71535D106 13G Page 3 of 5 Pages

     

    Item 1(a) Name of issuer:

     

    Personalis, Inc.

     

    Item 1(b) Address of issuer's principal executive offices:

     

    1330 O’Brien Drive

    Menlo Park, California 94025

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    200 Central Avenue

    St. Petersburg, FL 33701

     

    Item 2(c) Citizenship:

     

    Delaware, United States 

     

    Item 2(d) Title of class of securities:

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    71535D106

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

     

    CUSIP No. 71535D106 13G Page 4 of 5 Pages

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ 

     

    Item 4. Ownership

     

    (a)Amount beneficially owned:

     

    5,500,400

     

    (b)Percent of class:

     

    11.96%

     

    (c)Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  5,500,400

     

    (ii) Shared power to vote or to direct the vote:  0

     

    (iii) Sole power to dispose or to direct the disposition of: 5,500,400

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

      

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    CUSIP No. 71535D106 13G Page 5 of 5 Pages

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    February 10, 2023

     

     

    ARK Investment Management LLC 

         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title: Chief Compliance Officer

     

     

     

    Get the next $PSNL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PSNL

    DatePrice TargetRatingAnalyst
    12/2/2025$11.00Equal-Weight
    Morgan Stanley
    5/15/2025$6.00Buy
    Guggenheim
    3/17/2025$8.00Buy
    Canaccord Genuity
    2/6/2023$8.00Hold → Buy
    Needham
    2/6/2023Hold → Buy
    Needham
    2/25/2022$30.00 → $24.00Outperform
    Oppenheimer
    2/25/2022$30.00 → $18.00Buy
    Citigroup
    2/25/2022$50.00 → $38.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PSNL
    SEC Filings

    View All

    SEC Form 8-K filed by Personalis Inc.

    8-K - Personalis, Inc. (0001527753) (Filer)

    3/17/26 4:17:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form S-8 filed by Personalis Inc.

    S-8 - Personalis, Inc. (0001527753) (Filer)

    2/26/26 5:11:47 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Personalis Inc.

    10-K - Personalis, Inc. (0001527753) (Filer)

    2/26/26 4:11:12 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l

    3/17/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The Pathologic Response Evaluation and Detection In Circulating Tumor-DNA (PREDICT-DNA) study: Ultrasensitive ctDNA Assessment of Breast Cancer Minimal Residual Disease," showed that ultrasensitive molecular residual disease (MRD) testing with NeXT Personal can perform better than current standard approaches in predicting patient outcomes following neoadjuvant therapy (NAT). The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading U

    3/12/26 6:00:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

    Clinical test volume surged 41% in Q4 over Q3 to 6,183 tests and full year increased nearly 400% to 16,233 tests Secured Medicare coverage for breast and lung cancer surveillance, validating ultrasensitive MRD technology Strong cash position of approximately $240 million provides capital for commercial expansion Full year 2026 revenue guidance of $78 to $80 million, driven by expected growth of approximately 5x for clinical revenue Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025 and recent business highlights and provided financial

    2/26/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Myers Woodrow A Jr bought $16,700 worth of shares (10,000 units at $1.67), increasing direct ownership by 62% to 26,116 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/5/24 5:15:53 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO AND COO Tachibana Aaron was granted 34,375 shares, increasing direct ownership by 21% to 198,833 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/17/26 4:59:16 PM ET
    $PSNL
    Medical Specialities
    Health Care

    SVP and Chief Legal Officer Moore Stephen Michael was granted 28,125 shares, increasing direct ownership by 44% to 92,325 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/17/26 4:57:49 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Chief Executive Officer Hall Christopher M was granted 87,500 shares, increasing direct ownership by 59% to 235,986 units (SEC Form 4)

    4 - Personalis, Inc. (0001527753) (Issuer)

    3/17/26 4:55:31 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley resumed coverage on Personalis with a new price target

    Morgan Stanley resumed coverage of Personalis with a rating of Equal-Weight and set a new price target of $11.00

    12/2/25 8:29:48 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Guggenheim initiated coverage on Personalis with a new price target

    Guggenheim initiated coverage of Personalis with a rating of Buy and set a new price target of $6.00

    5/15/25 8:13:23 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Canaccord Genuity initiated coverage on Personalis with a new price target

    Canaccord Genuity initiated coverage of Personalis with a rating of Buy and set a new price target of $8.00

    3/17/25 8:20:27 AM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Financials

    Live finance-specific insights

    View All

    Personalis to Announce Fourth Quarter and Full Year 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will

    2/12/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Reports Third Quarter 2025 Financial Results

    Company Advances "Win-in-MRD" Strategy with Compelling Clinical Trial Data and Increasing Physician Adoption of NeXT Personal® Platform Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2025. The quarter was distinguished by significant operational momentum in its "Win-in-MRD" strategy, headlined by increasing clinical tests delivered and robust clinical evidence generation. Third Quarter 2025 and Recent Business Highlights Accelerated Clinical Adoption: Delivered 4,388 clinical tests, demonstrating robust 26% sequential increase over Q2 2025 and a 364% year-over-year growth fu

    11/4/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis to Announce Third Quarter 2025 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shor

    10/21/25 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Leadership Updates

    Live Leadership Updates

    View All

    Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD Adoption

    Dr. Chen expands his leadership role to serve as President while continuing to serve as Chief Medical Officer (CMO), unifying R&D innovation with operational execution as Personalis defines the next era of ultrasensitive MRD testing Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, today announced the promotion of Richard Chen, M.D., M.S., to the position of President. Dr. Chen will continue to serve as CMO of Personalis in addition to his new role. The appointment comes at a critical inflection point as Personalis transitions from a pioneering R&D powerhouse into a market leader in Minimal Residual Disease (MRD) testing. Under Dr. Chen's scientific l

    3/17/26 4:00:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Personalis Appoints Former Roche Diagnostics and GRAIL Executive Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

    Bhandari to drive regulatory strategies for minimal residual disease (MRD) cancer test Personalis achieves ISO 13485:2016 certification, attesting to its ability to deliver medical devices and related services of the highest quality Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomic testing for precision oncology, today announced the appointment of Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance. With over two decades of industry marketing and regulatory affairs experience, Ms. Bhandari will help the company navigate the regulatory requirements for the NeXT Personal® MRD test. She was most recently VP, Regulatory Affairs at GRAIL, and previously held se

    10/18/23 7:15:00 AM ET
    $PSNL
    Medical Specialities
    Health Care

    Dr. Kenneth J. Widder Joins Personalis Board of Directors

    Personalis, Inc. (NASDAQ:PSNL) today announced that it has appointed Kenneth J. Widder, M.D., to its Board of Directors. Dr. Widder currently serves on the boards of QuidelOrtho Corporation and Evoke Pharma, Inc. and has over 40 years of experience working with biomedical companies, having previously served as a founder, director and/or CEO of Sydnexis, Inc., OrphoMed, Inc., Sytera, Inc., NovaCardia, Inc., Santarus, Inc., and Molecular Biosystems Inc., and as a general partner at LVP Life Science Ventures (formerly Latterell Venture Partners) and Windamere Venture Partners. He holds an M.D. from Northwestern University and trained in pathology at Duke University. "We are delighted to ha

    6/13/23 7:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    $PSNL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Personalis Inc.

    SC 13G/A - Personalis, Inc. (0001527753) (Subject)

    8/19/24 6:03:38 AM ET
    $PSNL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Personalis Inc.

    SC 13G - Personalis, Inc. (0001527753) (Subject)

    7/26/24 12:56:21 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13D/A filed by Personalis Inc.

    SC 13D/A - Personalis, Inc. (0001527753) (Subject)

    6/28/24 4:01:17 PM ET
    $PSNL
    Medical Specialities
    Health Care